Kalinox (Nitrous Oxide, Oxygen)

Nitrous oxide in Kalinox blocks NMDA receptors and enhances opioid and GABAergic neurotransmission, producing rapid analgesia and sedation while the oxygen component maintains adequate tissue oxygenation throughout the procedure.

The dose of Kalinox is individualized. A qualified prescriber determines the appropriate concentration of nitrous oxide and oxygen based on the patient’s age, weight, clinical condition, and the specific procedure being performed.

Safety data for Kalinox in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and only under close medical supervision.

To order Kalinox, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with volatile agents such as sevoflurane, Kalinox offers a rapid onset and offset of effect, minimal metabolism, and the ability to titrate analgesia while preserving spontaneous breathing. It is generally less potent than full‑strength volatile anesthetics but provides a favorable safety profile for short‑duration procedures.

Kalinox cylinders should be stored at ambient temperature, kept upright, and protected from heat, direct sunlight and physical damage. Ensure cylinders are secured to prevent tipping and that the delivery system is inspected regularly for leaks before each use.

Kalinox is delivered via a calibrated inhalation system, such as a mask or nasal hood, allowing precise control of the nitrous oxide‑oxygen mixture. The clinician adjusts the flow to achieve the desired analgesic effect while continuously monitoring the patient’s vital signs.

Serious risks include respiratory depression, severe hypotension, loss of consciousness, pulmonary edema, and rare allergic reactions. Continuous monitoring of oxygen saturation and respiratory function is essential to detect and manage these events promptly.

Kalinox is contraindicated in patients with known hypersensitivity to nitrous oxide or oxygen, those with severe chronic obstructive pulmonary disease, uncontrolled asthma, or any condition that impairs the ability to maintain adequate ventilation without assistance.